Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 9 de 9
1.
Postgrad Med J ; 97(1143): 10-15, 2021 Jan.
Article En | MEDLINE | ID: mdl-33055193

BACKGROUND: Little is known about the impact of the provision of handheld point-of-care ultrasound (POCUS) devices on physical examination skills of medical students. METHODS: We describe an educational initiative that comprised a POCUS workshop followed by allocation of a POCUS device to medical students for use over the subsequent 8 weeks. They were encouraged to scan patients and correlate their physical examination findings. A mobile instant messaging group discussion platform was set to provide feedback from instructors. Physical examination skills were assessed by means of clinical examination. RESULTS: 210 final-year medical students from the University of Hong Kong participated in the programme. 46.3% completed the end of programme electronic survey: 74.6% enjoyed using the POCUS device, 50.0% found POCUS useful to validate physical examination findings and 47.7% agreed that POCUS increased their confidence with physical examination. 93.9% agreed that the programme should be incorporated into the medical curriculum and 81.9% would prefer keeping the device for longer time from 16 weeks (45.6%) to over 49 weeks (35.3%). Medical students who participated in the POCUS programme had a higher mean score for abdominal examination compared with those from the previous academic year with no POCUS programme (3.65±0.52 vs 3.21±0.80, p=0.014), but there was no statistically significant difference in their mean score for cardiovascular examination (3.62±0.64 vs 3.36±0.93, p=0.203). CONCLUSION: The POCUS programme that included provision of a personal handheld POCUS device improved students' attitude, confidence and ability to perform a physical examination.


Clinical Competence , Education, Medical, Undergraduate , Physical Examination , Point-of-Care Systems , Ultrasonography , Curriculum , Hong Kong , Humans
2.
Europace ; 18(5): 665-71, 2016 May.
Article En | MEDLINE | ID: mdl-26504109

AIMS: Little is known about the ischaemic stroke risk and benefit of warfarin therapy for stroke prevention in chronic kidney disease (CKD) patients on peritoneal dialysis (PD) with concomitant atrial fibrillation (AF). Our objective was to determine the risk of ischaemic stroke in a 'real-world' cohort of PD patients with AF, and clinical benefit or harm of aspirin and warfarin. METHODS AND RESULTS: This is a single-centred observational study of Chinese patients with non-valvular AF. Hospitalizations with ischaemic stroke and intracranial haemorrhage (ICH) were recorded. Of 9810 patients from a hospital-based AF registry, 271 CKD patients on PD with AF (76.8 ± 12.5 years, CHA2DS2-VASc: 3.69 ± 1.83, and HAS-BLED: 2.07 ± 0.97) were identified. Amongst these PD patients, 24.7% received warfarin; 31.7% received aspirin; and 43.5% received no antithrombotic therapy. Amongst patients with no antithrombotic therapy, annual incidence of ischaemic stroke in PD patients was comparable with those non-CKD counterparts (9.32 vs. 9.30%/year). Similar to non-CKD patients, annual incidence of ischaemic stroke increased with increasing CHA2DS2-VASc score (CHA2DS2-VASc = 0-1: 5.76 vs. 5.70%/year, P = 1.00; and CHA2DS2-VASc ≥ 2: 10.80 vs. 9.94%/year, P = 0.78). Amongst PD patients, warfarin therapy was associated with lower risk of ischaemic stroke compared with aspirin [Hazard ratio (HR): 0.16, 95% confidence interval (CI): 0.04-0.66, P = 0.01] and no therapy (HR: 0.19, 95% CI: 0.06-0.65, P = 0.01), but not associated with a higher risk of ICH. CONCLUSION: In CKD patients on PD with AF, who had similar ischaemic stroke risk as non-CKD counterparts, warfarin therapy is associated with reduction in risk of ischaemic stroke without a higher risk of ICH.


Anticoagulants/therapeutic use , Aspirin/therapeutic use , Atrial Fibrillation/complications , Atrial Fibrillation/drug therapy , Renal Insufficiency, Chronic/epidemiology , Stroke/epidemiology , Warfarin/therapeutic use , Aged , Aged, 80 and over , Female , Hong Kong , Hospitalization , Humans , Incidence , Kaplan-Meier Estimate , Male , Middle Aged , Peritoneal Dialysis , Proportional Hazards Models , Registries , Renal Insufficiency, Chronic/therapy , Risk Assessment , Risk Factors , Stroke/prevention & control
3.
Clin Transplant ; 18(3): 274-80, 2004 Jun.
Article En | MEDLINE | ID: mdl-15142048

OBJECTIVES: Hyperlipidemia is a common and important risk factor after renal transplantation, but there is little long-term data on its incidence, pattern, and evolution in stable renal allograft recipients on low dose maintenance immunosuppression. PATIENTS AND METHODS: A retrospective study was conducted on all patients who received kidney transplants from April 1, 1990 to March 31, 2000 at a single center, on their serial lipid profile during the first 3 yr after kidney transplantation. RESULTS: A total of 221 (122 male, 99 female; mean age 37.8 +/- 10.0 yr at the time of transplantation) Chinese adult renal allograft recipients were included. A 95.3% of patients were on cyclosporine and prednisolone based immunosuppression. Increases in total cholesterol (TC), low density lipoprotein (LDL), and high density lipoprotein (HDL) were noted, while the level of triglyceride (TG) decreased after renal transplant. The incidence of hypercholesterolemia (defined as TC >/= 6.3 mmol/L or LDL >/= 4.2 mmol/L) within the first year was 28.2 and 20.3%, respectively. The incidence rate decreased significantly in the second (5.4%, p = 0.000 and 6.4%, p = 0.003) and third year (9.5%, p = 0.003 and 4.9%, p = 0.021), but the incidence of patients having a high risk-ratio (defined as TC/HDL >/= 5) remained unchanged (6.9, 4.9 and 10.3% within the first, second, and third year, respectively). Treatment with statin was necessitated in 6.8, 13.6 and 21.7% of the patients at 1, 2, and 3 yr after transplantation, respectively. The prevalence rates of elevated TC and LDL were 18.3 and 18.9% at baseline, 40.6 and 33.3% after 1 yr, 32.8 and 27.3% after 2 yr, and 24.8 and 19.0% after 3 yr, despite treatment. The prevalence of patients with a high risk-ratio was 45.0% at baseline, 30.5% after 1 yr (p = 0.002), 22.6% after 2 yr (p = 0.000) and 21.8% after 3 yr (p = 0.000). Hypercholesterolemia at the time of transplantation was an independent predictor for post-transplant hypercholesterolemia (odds ratio 3.76, 95% confidence interval 1.47-9.62, p = 0.006). CONCLUSION: Renal transplantation is associated with a characteristic pattern of dyslipidemia, with increased TC, LDL and HDL, and a decrease in TG. Patients with pre-existing hypercholesterolemia were at higher risk for post-transplant hypercholesterolemia. Although the incidence of hypercholesterolemia peaks within the first year after transplantation, this remains a long-term complication in a significant proportion of patients on low dose immunosuppressive medications.


Adrenal Cortex Hormones/adverse effects , Cyclosporine/adverse effects , Hyperlipidemias/complications , Immunosuppressive Agents/adverse effects , Kidney Transplantation/adverse effects , Adult , Diet , Female , Hong Kong , Humans , Hyperlipidemias/epidemiology , Incidence , Male , Middle Aged , Prevalence , Retrospective Studies , Risk Factors , Time Factors
4.
Perit Dial Int ; 23(5): 504-6, 2003.
Article En | MEDLINE | ID: mdl-14604207

OBJECTIVE: To determine the feasibility of reinstitution of continuous ambulatory peritoneal dialysis (CAPD) in patients with malignant hepatic tumors after partial hepatectomy. DESIGN: Retrospective analysis of 2 CAPD patients. SETTING: Dialysis unit of a university teaching hospital. PATIENTS: Two CAPD patients with malignant hepatic tumors who had undergone partial hepatectomy. MAIN OUTCOME MEASURES: Serum biochemistry, Kt/V, peritoneal equilibration test (PET) results before and after hepatectomy. RESULTS: One patient was able to resume CAPD 4 weeks after partial hepatectomy. The other patient was successfully resumed on CAPD after resting the peritoneum for 3 months following partial hepatectomy. The serum biochemistry, Kt/V, and PET results of the 2 patients did not change significantly before and after partial hepatectomy. CONCLUSIONS: Reinstitution of CAPD after partial hepatectomy in patients with malignant hepatic tumors is feasible.


Bile Duct Neoplasms/surgery , Hepatectomy , Kidney Failure, Chronic/therapy , Liver Neoplasms/surgery , Peritoneal Dialysis, Continuous Ambulatory , Aged , Bile Duct Neoplasms/complications , Carcinoma, Hepatocellular/complications , Carcinoma, Hepatocellular/surgery , Cystadenocarcinoma/complications , Cystadenocarcinoma/surgery , Feasibility Studies , Female , Humans , Kidney Failure, Chronic/complications , Liver Neoplasms/complications , Male , Middle Aged , Retreatment , Retrospective Studies
5.
Nephrol Dial Transplant ; 18(7): 1316-20, 2003 Jul.
Article En | MEDLINE | ID: mdl-12808168

INTRODUCTION: Minimal change nephrotic syndrome (MCNS) is a common form of nephrotic syndrome in children and young adults. We investigated its clinical presentations, steroid responsiveness, subsequent clinical course and patterns of relapse in older adults in whom it was diagnosed after the age of 50 years. METHODS: The clinical records of renal patients followed-up in a single out patient clinic were retrieved and those patients with biopsy-proven MCNS were included. Patients in the 18-50-year age range (Group A) at the time of biopsy were compared with those older than 50 years (Group B) with regard to baseline demographic data, clinical features and outcome of treatment. RESULTS: In all, 50 patients were studied, 35 in Group A (age at diagnosis: 38.8+/-11.91 years) and 15 in Group B (age at diagnosis: 70+/-6.85 years), with an overall follow-up duration of 72.08+/-63.42 months. Group B had a higher prevalence of hypertension and lower creatinine clearance at presentation, but the values of creatinine clearance for both groups were comparable with age-matched controls. One patient from Group B and two from Group A had spontaneous remission. Complete remission was achieved in 9.09, 45.45, 90.91 and 100% of Group B patients and 15.63, 62.5, 87.5 and 93.75% of Group A patients after 2, 4, 8 and 16 weeks of steroid therapy, respectively. The median time to complete remission and the duration of steroid treatment were similar for both groups. From Group B five patients and 22 patients from Group A relapsed during follow-up (P=0.055), with similar proportions of each group being early relapsers or frequent relapsers. The average number of relapses was 2.06 episodes for Group A, compared with 0.87 episodes for group B (P=0.062). Second agents were used in 20 Group A and four Group B patients (P=0.048). Complications of treatment were more common in Group A. None of the patients developed doubling of serum creatinine during follow-up. CONCLUSIONS: Clinical presentations of older patients with MCNS were similar to younger patients apart from the age-related decline of renal function and higher prevalence of hypertension. Both groups have similar steroid responsiveness, but older patients tend to have fewer relapses and require fewer second agents for treatment of relapses.


Anti-Inflammatory Agents/therapeutic use , Nephrosis, Lipoid/drug therapy , Nephrosis, Lipoid/pathology , Outcome Assessment, Health Care , Prednisolone/therapeutic use , Adolescent , Adult , Age Factors , Aged , Female , Follow-Up Studies , Humans , Male , Middle Aged , Recurrence , Remission Induction , Severity of Illness Index , Time Factors
6.
Nephrol Dial Transplant ; 18(1): 182-6, 2003 Jan.
Article En | MEDLINE | ID: mdl-12480979

BACKGROUND: Fabry's disease is an X-linked recessive inborn error of glycosphingolipid catabolism resulting from deficient activity of lysosomal enzyme alpha-galactosidase A causing occlusive microvascular diseases affecting the kidney, heart, peripheral nerves and brain. It is an uncommon disease in the Oriental population. METHODS AND RESULTS: We report a Chinese kindred of Fabry's disease and the relevant clinical features are discussed. The diagnosis of Fabry's disease was based on serum alpha-galactosidase A activity and typical histological features from renal biopsy in the index patient. Genetic analysis of two hemizygous male patients revealed a missense mutation predicting a leucine to proline substitution (L14P) in the alpha-galactosidase gene causing classical Fabry's disease in this family. This is a novel point mutation not described previously in the literature and the second report describing novel genetic mutations for Fabry's disease in Chinese patients. CONCLUSIONS: Fabry's disease is rare in Chinese patients but this diagnosis should be considered in patients with positive family history of kidney disease and relevant clinical features.


Asian People/genetics , Chromosomes, Human, X , Fabry Disease/genetics , alpha-Galactosidase/genetics , Adult , Base Sequence , China , Chromosome Banding , DNA Primers , Exons , Fabry Disease/enzymology , Fabry Disease/physiopathology , Female , Genetic Carrier Screening , Humans , Male , Middle Aged , Pedigree , Proteinuria , Renal Insufficiency/etiology
7.
Perit Dial Int ; 22(4): 488-91, 2002.
Article En | MEDLINE | ID: mdl-12322820

OBJECTIVES: To study the clinical features, clinical outcomes, and peritoneal transport characteristics of patients with recurrent hemoperitoneum complicating continuous ambulatory peritoneal dialysis (CAPD). DESIGN: Single-center retrospective case review of patients on CAPD over a 10-year period. SETTING: Renal Unit in Queen Mary Hospital, a tertiary-care referral center in Hong Kong. PATIENTS: 549 patients were available for review. 46 patients (8.4%) had at least one episode of hemoperitoneum during their course of CAPD; 25 patients had only one episode of hemoperitoneum and they were excluded. The remaining 21 patients (3.8%) had two or more episodes of hemoperitoneum and they were included for review. MAIN OUTCOME MEASURES: Basic demographic factors and the etiology and episodes of hemoperitoneum were recorded. Clinical outcomes included continuation on peritoneal dialysis, conversion to hemodialysis (HD), renal transplantation, and death. The reason for conversion to HD, the causes of death, and serial peritoneal equilibration tests (PET) using dialysate-to-plasma ratio of creatinine (D/P creat) and ratio of dialysate glucose at hours 4 and zero of the dwell (D4/D0) with standard 2-L 2.5% glucose dialysate were assessed. RESULTS: There were 549 patients with total of 91 episodes of recurrent hemoperitoneum affecting 21 patients (3.8%). Mean age was 50.2 years (range 24-76 years) and mean duration of dialysis was 61.6 months (range 2-166 months). There were 14 female patients (66.7%) and 7 male patients (33.3%). The average number of hemoperitoneum episodes was 4.3 per patient (range 2-12). The mean time interval of the first hemoperitoneum episode from commencement of peritoneal dialysis was 10.5 months (range 1-37 months, SD 9.7 months). Most cases were due to retrograde menstruation in females and unknown cause in males. Two patients had intra-abdominal pathology accounting for hemoperitoneum. Thirteen patients (61.9%) continued CAPD, 2 (9.5%) underwent renal transplantation, and 2 (9.5%) were converted to long-term HD. The reason for conversion to HD was related to hemoperitoneum in 1 patient (4.8%) only. Four patients (19.0%) died; the causes of death were unrelated to hemoperitoneum. There was no correlation between recurrent hemoperitoneum and peritonitis episodes (p = 0.18). There was no significant association between hemoperitoneum episodes and clinical outcomes (p = 0.91) or survival (p = 0.52). None of the patients developed ultrafiltration failure on long-term follow-up. CONCLUSIONS: Recurrent hemoperitoneum is a benign complication of CAPD, with no significant long-term effects on patient survival, predisposition to peritonitis, or ultrafiltration failure.


Hemoperitoneum/etiology , Hemoperitoneum/therapy , Kidney Failure, Chronic/therapy , Peritoneal Dialysis, Continuous Ambulatory/adverse effects , Adult , Aged , Biological Transport , Female , Hemoperitoneum/mortality , Humans , Kidney Failure, Chronic/mortality , Male , Middle Aged , Outcome Assessment, Health Care , Recurrence , Retrospective Studies , Survival Rate , Time Factors
8.
Am J Kidney Dis ; 40(4): E14, 2002 Oct.
Article En | MEDLINE | ID: mdl-12324935

We report the case of a 72-year-old woman with a long-standing history of diabetes mellitus who presented with heavy proteinuria and rapid deterioration in renal function. She had a high titer of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA). The renal biopsy specimen revealed features of diabetic glomerulosclerosis, crescentic glomerulonephritis, and IgA nephropathy. Treatment with steroid and cyclophosphamide resulted in significant improvement in renal function and normalization of MPO-ANCA level. This case highlights the importance of having a high index of suspicion for coexisting glomerulonephritis in diabetic patients presenting with proteinuria. The clinical course of patients with diabetic glomerulosclerosis, IgA nephropathy, crescentic glomerulonephritis, and MPO-ANCA seropositivity seems to resemble that of ANCA-associated, rapidly progressive glomerulonephritis and is potentially amenable to aggressive immunosuppressive therapy.


Anti-Glomerular Basement Membrane Disease/complications , Antibodies, Antineutrophil Cytoplasmic/blood , Diabetic Nephropathies/complications , Glomerulonephritis, IGA/complications , Peroxidase/immunology , Aged , Anti-Glomerular Basement Membrane Disease/blood , Anti-Glomerular Basement Membrane Disease/drug therapy , Anti-Glomerular Basement Membrane Disease/enzymology , Antibodies, Antineutrophil Cytoplasmic/metabolism , China/ethnology , Diabetic Nephropathies/drug therapy , Female , Glomerulonephritis, IGA/drug therapy , Humans
9.
Clin Diagn Lab Immunol ; 9(2): 482-4, 2002 Mar.
Article En | MEDLINE | ID: mdl-11874897

Leptospirosis is a common zoonosis seen worldwide, but it is rare in our locality (Hong Kong). Clinical manifestations of leptospirosis are variable and may range from subclinical infection to fever, jaundice, hemorrhagic tendency, and fulminant hepato-renal failure. Severe hyperbilirubinemia and acute renal failure have been associated with high mortality. We report our experience with a patient who developed severe Weil's syndrome with marked conjugated hyperbilirubinemia and oliguric acute renal failure. These complications persisted despite treatment with penicillin and hemodiafiltration. Plasma exchange was instituted in view of the severe hyperbilirubinemia (970 micromol/liter). This was followed by prompt clinical improvement, with recovery of liver and renal function. The beneficial effects of plasma exchange could be attributed to amelioration of the toxic effects of hyperbilirubinemia on hepatocyte and renal tubular cell function. We conclude that plasma exchange should be considered as an adjunctive therapy for patients with severe icteric leptospirosis complicated by acute renal failure who have not shown rapid clinical response to conventional treatment.


Acute Kidney Injury/microbiology , Plasma Exchange , Weil Disease/complications , Weil Disease/therapy , Adult , Humans , Hyperbilirubinemia/complications , Hyperbilirubinemia/microbiology , Hyperbilirubinemia/therapy , Jaundice/complications , Jaundice/microbiology , Jaundice/therapy , Male
...